Stephen B. Kay Family Professor of Medicine
Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, Wurster-Hill D, Noll W, Elghetany MT, Allen SL
Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991 May 15; 77(10):2242-50.
Prognostic value of lymphocyte surface markers in acute myeloid leukemia.
Follow-up strategies after curative resection of colorectal cancer. Semin Oncol. 2003 Jun; 30(3):349-60.
Follow-up strategies after curative resection of colorectal cancer.
Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD, Nathan DG, Frei E
The treatment of acute myelogenous leukemia in children and adults: VAPA update. Haematol Blood Transfus. 1983; 28:41-5.
The treatment of acute myelogenous leukemia in children and adults: VAPA update.
Mayer RJ, Weinstein HJ, Coral FS, Rosenthal DS, Frei E
The role of intensive postinduction chemotherapy in the management of patients with acute myelogenous leukemia. Cancer Treat Rep. 1982 Jul; 66(7):1455-62.
The role of intensive postinduction chemotherapy in the management of patients with acute myelogenous leukemia.
Arnold CN, Goel A, Compton C, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther. 2004 Jan; 3(1):73-8.
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer.
Journal of the National Cancer Institute
Training in medical oncology: regaining the luster. J Natl Cancer Inst. 1991 Jun 19; 83(12):806-7.
Training in medical oncology: regaining the luster.
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: follow-up report. J Hepatic Biliary Pancreatic Surg. 1995; 2:122-125.
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: follow-up report
Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ
Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988 Mar; 71(3):690-6.
Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.
Goldberg MA, Ginsburg D, Mayer RJ, Stone RM, Maguire M, Rosenthal DS, Antin JH
Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood. 1987 Jan; 69(1):187-91.
Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?
Amsacrine in refractory acute leukemia. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):787-9.
Mayer RJ, Garnick MB, Steele GD, Zamcheck N
Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer. 1978 Sep; 42(3 Suppl):1428-33.
Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer.
Goslin R, Steele G, Zamcheck N, Mayer R, MacIntyre J
Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum. 1982 Nov-Dec; 25(8):749-54.
Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum.
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998 Sep 15; 58(18):4173-9.
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Chemotherapy for metastatic colorectal cancer. Cancer. 1992 Sep 01; 70(5 Suppl):1414-24.
Chemotherapy for metastatic colorectal cancer.
Hilden JM, Emanuel EJ, Fairclough DL, Link MP, Foley KM, Clarridge BC, Schnipper LE, Mayer RJ
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Attitudes and practices among pediatric oncologists regarding end-of-life care: results of the 1998 American Society of Clinical Oncology survey. J Clin Oncol. 2001 Jan 01; 19(1):205-12.
Attitudes and practices among pediatric oncologists regarding end-of-life care: results of the 1998 American Society of Clinical Oncology survey.
Gallo RC, Gallagher RE, Miller NR, Mondal H, Saxinger WC, Mayer RJ, Smith RG, Gillespie DH
Cold Spring Harbor symposia on quantitative biology
Relationships between components in primate RNA tumor viruses and in the cytoplasm of human leukemic cells: implications to leukemogenesis. Cold Spring Harb Symp Quant Biol. 1975; 39 Pt 2:933-61.
Relationships between components in primate RNA tumor viruses and in the cytoplasm of human leukemic cells: implications to leukemogenesis.
Amrein PC, Davis RB, Mayer RJ, Schiffer CA
Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. Am J Hematol. 1990 Oct; 35(2):80-3.
Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
Joseph NE, Sigurdson ER, Hanlon AL, Wang H, Mayer RJ, MacDonald JS, Catalano PJ, Haller DG
Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003 Apr; 10(3):213-8.
Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection.
Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26.
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A
A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009 Apr 07; 6(4):e1000046.
A compendium of potential biomarkers of pancreatic cancer.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG
Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 01; 116(17):4007-13.
Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).
Shinagare AB, Ramaiya NH, Bellizzi AM, Mayer RJ
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months. Pancreatology. 2012 Jan-Feb; 12(1):35-8.
Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994 Aug 25; 331(8):502-7.
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.
Stone RM, Spriggs DR, Dhawan RK, Arthur KA, Mayer RJ, Kufe DW
A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. Leukemia. 1990 Dec; 4(12):843-7.
A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20; 24(9):1395-403.
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007 Jan; 132(1):127-38.
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008 Sep 01; 26(25):4109-15.
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 2003 Apr 01; 63(7):1608-14.
Characterization of sporadic colon cancer by patterns of genomic instability.
Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003; 21(4):505-11.
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB, Fuchs CS
Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol. 2004 Jan 01; 22(1):166-74.
Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.
Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA
Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr. 2018 Feb; 2(2):pky017.
Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R
Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991 Mar; 51(3):630-6.
Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation.
Cuttner J, Mick R, Budman DR, Mayer RJ, Lee EJ, Henderson ES, Weiss RB, Paciucci PA, Sobol R, Davey F
Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Leukemia. 1991 May; 5(5):425-31.
Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol. 2006 Jun 01; 24(16):2557-62.
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
Acute renal failure associated with neoplastic disease and its treatment. Semin Oncol. 1978 Jun; 5(2):155-65.
Acute renal failure associated with neoplastic disease and its treatment.
Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma. Cancer Res. 1980 Oct; 40(10):3430-6.
Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma.
Adjuvant chemotherapy for colon and rectal cancer. Semin Oncol. 1995 Oct; 22(5):472-87.
Adjuvant chemotherapy for colon and rectal cancer.
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 06; 331(14):896-903.
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
How is cancer treatment chosen? N Engl J Med. 1988 Mar 10; 318(10):636-8.
Kinsella TJ, Little JB, Nove J, Weichselbaum RR, Li FP, Mayer RJ, Marchetto D, Patterson WB
Heterogenous response to X-ray and UV light irradiation of cultured skin fibroblasts in two families with Gardner's syndrome. J Natl Cancer Inst. 1982; 68:697-701.
Heterogenous response to X-ray and UV light irradiation of cultured skin fibroblasts in two families with Gardner's syndrome
Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006 Oct 20; 24(30):4914-21.
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C, Ryan DP
Annals of oncology : official journal of the European Society for Medical Oncology
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul; 18(7):1185-9.
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Adjuvant therapy for colon cancer: Results of a prospectively randomized trial. N Engl J Med. 1984; 310:737-743.
Adjuvant therapy for colon cancer: Results of a prospectively randomized trial
Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244.
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).
Mayer RJ, Schiffer CA, Peterson BA, Silver RT, Cornwell GG, McIntyre OR, Rai KR, Budman DR, Ellison RR, Maguire M
Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study. Semin Oncol. 1985 Jun; 12(2 Suppl 3):84-90.
Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study.
Reverse transcriptase in normal rhesus monkey placenta. Science. 1974 Sep 06; 185(4154):864-7.
Reverse transcriptase in normal rhesus monkey placenta.
Weiss GR, Garnick MB, Osteen RT, Steele GD, Wilson RE, Schade D, Kaplan WD, Boxt LM, Kandarpa K, Mayer RJ
Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol. 1983 May; 1(5):337-44.
Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump.
Meropol NJ, Niedzwiecki D, Shank B, Colacchio TA, Ellerton J, Valone F, Budinger S, Day JM, Hopkins J, Tepper J, Goldberg RM, Mayer RJ
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol. 2008 Jul 01; 26(19):3229-34.
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
Provenzale D, Gupta S, Ahnen DJ, Markowitz AJ, Chung DC, Mayer RJ, Regenbogen SE, Blanco AM, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Hall MJ, Halverson AL, Hamilton SR, Hampel H, Klapman JB, Larson DW, Lazenby AJ, Llor X, Lynch PM, Mikkelson J, Ness RM, Slavin TP, Sugandha S, Weiss JM, Dwyer MA, Ogba N
Journal of the National Comprehensive Cancer Network : JNCCN
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. J Natl Compr Canc Netw. 2018 08; 16(8):939-949.
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.
Hematology/oncology clinics of North America
The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am. 1994 Jun; 8(3):533-53.
The use of serologic tumor markers in gastrointestinal malignancies.
Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst. 2012 Nov 21; 104(22):1702-11.
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Schnipper L, Bitran JD, Blank LL, Blum D, Brock D, Bruera E, Emanuel EJ, Foley KM, Gordon DS, Hilden JM, Kagan RA, Levy MH, Lichter As, Link MP, Penley WC, Smith TJ, Stanley K, Stovall E, TokazLK, Wood WC, Mayer R
Cancer care during the last phase of life. J Clin Oncol. 1998; 5:1986-1996.
Cancer care during the last phase of life
Griffin JD, Mayer RJ, Weinstein HJ, Rosenthal DS, Coral FS, Beveridge RP, Schlossman SF
Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotypes. Blood. 1983 Sep; 62(3):557-63.
Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotypes.
Summary of the Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Ann Oncol. 1995 Sep; 6(7):645-9.
Summary of the Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies.
Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol. 1987 Dec; 14(4):384-96.
Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia.
Adjuvant therapy in rectal cancer: a protocol proposal. Semin Oncol. 1985 Sep; 12(3 Suppl 4):116-20.
Adjuvant therapy in rectal cancer: a protocol proposal.
Steele G, Osteen RT, Wilson RE, Brooks DC, Mayer RJ, Zamcheck N, Ravikumar TS
Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy. Am J Surg. 1984 Apr; 147(4):554-9.
Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy.
Davey FR, Abraham N, Brunetto VL, MacCallum JM, Nelson DA, Ball ED, Griffin JD, Baer MR, Wurster-Hill D, Mayer RJ
Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. Am J Hematol. 1995 May; 49(1):29-38.
Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study.
Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 01; 25(1):146-62.
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70.
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Intensive chemotherapy versus allogeneic bone marrow transplantation in first-remission acute myeloid leukemia. Bone Marrow Transplant. 1990 Jul; 6 Suppl 1:48-51.
Intensive chemotherapy versus allogeneic bone marrow transplantation in first-remission acute myeloid leukemia.
Primary central nervous system lymphoma. Ann Intern Med. 1993 Dec 01; 119(11):1093-104.
Primary central nervous system lymphoma.
Rai KR, Cuttner J, Holland JF, Davis R, Mayer R, McIntyre OR, Preisler H, Yates J
Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B. Haematol Blood Transfus. 1987; 30:31-4.
Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B.
Schiffer CA, Davis RB, Mayer RJ, Peterson BA, Lee EJ
Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study. Cancer Treat Rep. 1987 Sep; 71(9):879-80.
Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.
Douglass HO, Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A, Stablein DM, Bruckner HW
Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986 11 13; 315(20):1294-5.
Survival after postoperative combination treatment of rectal cancer.
Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer. Cancer. 1977 Dec; 40(6):2792-6.
Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer.
More than MOPP for advanced Hodgkin's disease? N Engl J Med. 1982 Apr 01; 306(13):800-2.
More than MOPP for advanced Hodgkin's disease?
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am. 1993 Feb; 7(1):47-64.
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
Mayer RJ, Hochster HS, Cohen SJ, Winkler R, Makris L, Grothey A
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2018 12; 82(6):961-969.
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Spriggs DR, Robbins G, Arthur K, Mayer RJ, Kufe D
Prolonged high dose ARA-C infusions in acute leukemia. Leukemia. 1988 May; 2(5):304-6.
Prolonged high dose ARA-C infusions in acute leukemia.
Goslin R, Steele G, Macintyre J, Mayer R, Sugarbaker P, Cleghorn K, Wilson R, Zamcheck N
The use of preoperative plasma CEA levels for the Stratification of patients after curative resection of colorectal cancers. Ann Surg. 1980 Dec; 192(6):747-51.
The use of preoperative plasma CEA levels for the Stratification of patients after curative resection of colorectal cancers.
Bruckner HW, Douglass HO Jr., Mayer RJ, Leichman LP, Stablein DM
Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. J Natl Cancer Inst. 1988; 80:1011-1015.
Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer
Mayer RJ, Antman KH, Bailes JS, Bloomfield CD, Canellos GP, Glick JH, Jacobs CD
The status of the medical oncology workforce a report from the ad hoc committee of the American Society of Clinical Oncology. J Clin Oncol. 1996; 14:2612-2621.
The status of the medical oncology workforce a report from the ad hoc committee of the American Society of Clinical Oncology
Emanuel EJ, Fairclough D, Clarridge BC, Blum D, Bruera E, Penley WC, Schnipper LE, Mayer RJ
Attitudes and practices of U.S. oncologists regarding euthanasia and physician-assisted suicide. Ann Intern Med. 2000 Oct 03; 133(7):527-32.
Attitudes and practices of U.S. oncologists regarding euthanasia and physician-assisted suicide.
Oxaliplatin-induced Evan's syndrome. Br J Cancer. 2001 Feb 02; 84(3):441.
Krasna MJ, Reed CE, Nedzwiecki D, Hollis DR, Luketich JD, DeCamp MM, Mayer RJ, Sugarbaker DJ
CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. Ann Thorac Surg. 2001 Apr; 71(4):1073-9.
CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer.
Greenberg R, Pearlman C, Brooks R, Mayer RJ, hartman E.
Dreaming and Korsakoff's psychosis. Arch Gen Psychiatry. 1968; 18:203-209.
Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, Goldberg RM
International journal of radiation oncology, biology, physics
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):386-96.
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.
Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD
Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood. 1983 Aug; 62(2):315-9.
Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update.
Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA
Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993 Nov 17; 85(22):1839-44.
Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
Testicular self-examination. N Engl J Med. 1980 Jan 31; 302(5):297.
The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am. 1993 Feb; 7(1):65-79.
The approach to the elderly patient with acute myeloid leukemia.
A step forward in the treatment of advanced biliary tract cancer. N Engl J Med. 2010 Apr 08; 362(14):1335-7.
A step forward in the treatment of advanced biliary tract cancer.
Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhoupt B, Park E, Jensen J, Coral F, Mayer RJ, Sallan SE
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest. 1984 Aug; 74(2):332-40.
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.
Tantravahi R, Griffin JD, Henkle C, Leavitt PR, Mayer RJ, Frei E
Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type). Cancer Genet Cytogenet. 1983 Oct; 10(2):167-75.
Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type).
Jessup JM, Steele G, Mayer RJ, Posner M, Busse P, Cady B, Stone M, Jenkins R, Osteen R
Archives of surgery (Chicago, Ill. : 1960)
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993 May; 128(5):559-64.
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma.
DNA-metabolizing enzymes in normal human lymphoid cells. VI. Induction of DNA polymerases alpha, beta, and gamma following stimulation with phytohemagglutinin. Blood. 1975 Oct; 46(4):509-18.
DNA-metabolizing enzymes in normal human lymphoid cells. VI. Induction of DNA polymerases alpha, beta, and gamma following stimulation with phytohemagglutinin.
The state of the society: a year of continued growth. J Clin Oncol. 1998 Sep; 16(9):3192-8.
The state of the society: a year of continued growth.
Moving beyond fluorouracil for colorectal cancer. N Engl J Med. 2000 Sep 28; 343(13):963-4.
Moving beyond fluorouracil for colorectal cancer.
Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004 May 01; 64(9):3014-21.
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.
Systemic therapy for colorectal cancer: an overview. Semin Oncol. 1991 Oct; 18(5 Suppl 7):62-6.
Systemic therapy for colorectal cancer: an overview.
Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005 Dec 01; 23(34):8706-12.
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
Farag SS, Archer KJ, Mrózek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73.
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Gastroenterology clinics of North America
Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Sep; 35(3):713-27.
Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease.
Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, Burks D, Kusek JW, Nyberg LM, Foster HE
Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin? J Urol. 2007 Sep; 178(3 Pt 1):886-90.
Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin?
Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Davey FR, Davis RB, MacCallum JM, Nelson DA, Mayer RJ, Ball ED, Griffin JD, Schiffer CA, Bloomfield CD
Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989 Apr; 30(4):221-7.
Morphologic and cytochemical characteristics of acute promyelocytic leukemia.
Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989 Oct; 7(10):1419-26.
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS
Clinical cancer research : an official journal of the American Association for Cancer Research
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900.
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Goldhaber SZ, Dricker E, Buring JE, Eberlein K, Godleski JJ, Mayer RJ, Hennekens CH
Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients. Am Heart J. 1987 Dec; 114(6):1432-5.
Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients.
Garnick MB, Blum RH, Canellos GP, Mayer RJ, Parker L, Skarin AT, Li FP, Henderson IC, Frei E
Phase I trial of bruceantin. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1929-32.
Goslin R, O'Brien MJ, Steele G, Mayer R, Wilson R, Corson JM, Zamcheck N
Correlation of Plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med. 1981 Aug; 71(2):246-53.
Correlation of Plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer.
Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S
European journal of cancer (Oxford, England : 1990)
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer. 2019 04; 111:82-93.
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
Antineoplastic Combined Chemotherapy Protocols
Harvard T.H. Chan School of Public Health
Shelby Memorial Professor of Medicine in the Field of Cancer Therapeutics
Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology, Emerita
Daniel K. Podolsky Professor of Medicine
Reasons of reduced physical activity in preconception and pregnancy. Minerva Med. 2023 02; 114(1):90-91.
Reasons of reduced physical activity in preconception and pregnancy.
Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 10 10; 37(29):2620-2631.
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K
Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2019 12 15; 25(24):7497-7505.
Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg R, O'Reilly EM, Meyerhardt JA, Ng K
Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2022 03 08; 114(3):427-435.
Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
McCleary NJ, Zhang S, Ma C, Ou FS, Bainter TM, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. J Geriatr Oncol. 2022 05; 13(4):469-479.
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
Keller RB, Mazor T, Sholl L, Aguirre AJ, Singh H, Sethi N, Bass A, Nagaraja AK, Brais LK, Hill E, Hennessey C, Cusick M, Del Vecchio Fitz C, Zwiesler Z, Siegel E, Ovalle A, Trukhanov P, Hansel J, Shapiro GI, Abrams TA, Biller LH, Chan JA, Cleary JM, Corsello SM, Enzinger AC, Enzinger PC, Mayer RJ, McCleary NJ, Meyerhardt JA, Ng K, Patel AK, Perez KJ, Rahma OE, Rubinson DA, Wisch JS, Yurgelun MB, Hassett MJ, MacConaill L, Schrag D, Cerami E, Wolpin BM, Nowak JA, Giannakis M
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer. JCO Precis Oncol. 2023 01; 7:e2200342.
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.
Huffman BM, Singh H, Ali LR, Horick N, Wang SJ, Hoffman MT, Metayer KA, Murray S, Bird A, Abrams TA, Biller LH, Chan JA, Meyerhardt JA, McCleary NJ, Goessling W, Patel AK, Wisch JS, Yurgelun MB, Mouw K, Reardon B, Van Allen EM, Zerillo JA, Clark JW, Parikh A, Mayer RJ, Schlechter B, Ng K, Kumar S, Del Vecchio Fitz C, Kuperwasser C, Hanna GJ, Coveler AL, Rubinson DA, Welsh EL, Pfaff K, Rodig S, Dougan SK, Cleary JM
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders. J Immunother Cancer. 2024 01 25; 12(1).
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.
Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2013 May; 71(5):1241-6.
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Dillmon M, Goldberg JM, Ramalingam SS, Mayer RJ, Loehrer P, Van Poznak C
Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologist. J Oncol Pract. 2012 Nov; 8(6):350-3, 2 p following 353.
Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologist.
Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98.
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer. 2013 Dec; 12(4):233-8.
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol. 2014 May 20; 32(15):1521-30.
Progress against GI cancer during the American Society of Clinical Oncology's first 50 years.
Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan; 107(1):345.
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14; 372(20):1909-19.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Provenzale D, Jasperson K, Ahnen DJ, Aslanian H, Bray T, Cannon JA, David DS, Early DS, Erwin D, Ford JM, Giardiello FM, Gupta S, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Rao MS, Regenbogen SE, Shike M, Steinbach G, Weinberg D, Dwyer MA, Freedman-Cass DA, Darlow S
Colorectal Cancer Screening, Version 1.2015. J Natl Compr Canc Netw. 2015 Aug; 13(8):959-68; quiz 968.
Colorectal Cancer Screening, Version 1.2015.
Kageyama S, Sou YS, Uemura T, Kametaka S, Saito T, Ishimura R, Kouno T, Bedford L, Mayer RJ, Lee MS, Yamamoto M, Waguri S, Tanaka K, Komatsu M
Proteasome dysfunction activates autophagy and the Keap1-Nrf2 pathway. J Biol Chem. 2014 Sep 05; 289(36):24944-55.
Proteasome dysfunction activates autophagy and the Keap1-Nrf2 pathway.
Nickel JC, Tripp D, Teal V, Propert KJ, Burks D, Foster HE, Hanno P, Mayer R, Payne CK, Peters KM, Kusek JW, Nyberg LM
Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J Urol. 2007 May; 177(5):1832-6.
Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis.
Development of glomerulations in younger women with interstitial cystitis. Urology. 2006 Aug; 68(2):253-6.
Development of glomerulations in younger women with interstitial cystitis.
Reply to A. Grothey et al and R.S. Midgley et al. J Clin Oncol. 2013 Apr 20; 31(12):1612-3.
Reply to A. Grothey et al and R.S. Midgley et al.
Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo. J Urol. 2008 Feb; 179(2):552-5.
Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo.
Burt RW, Cannon JA, David DS, Early DS, Ford JM, Giardiello FM, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Jasperson K, Klapman JB, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Dwyer M, Freedman-Cass D
Colorectal cancer screening. J Natl Compr Canc Netw. 2013 Dec 01; 11(12):1538-75.
Katz L, Tripp DA, Nickel JC, Mayer R, Reimann M, van Ophoven A
Disability in women suffering from interstitial cystitis/bladder pain syndrome. BJU Int. 2013 Jan; 111(1):114-21.
Disability in women suffering from interstitial cystitis/bladder pain syndrome.
By the way, doctor. We have screening tests for other cancers. How about pancreatic cancer? Harv Health Lett. 2009 May; 34(7):1.
By the way, doctor. We have screening tests for other cancers. How about pancreatic cancer?
Bohanes P, Rankin CJ, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martensen JA, Benson AB, Mayer RJ, Cripps CM, Danenberg K, Makar KW, Zhang W, Benedetti JK, Lenz HJ
Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res. 2015 Apr 01; 21(7):1583-90.
Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):638-45.
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, Culkin DJ, Diokno A, Hanno P, Landis JR, Madigan R, Messing EM, Nickel JC, Sant GR, Warren J, Wein AJ, Kusek JW, Nyberg LM, Foster HE
A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol. 2005 Apr; 173(4):1186-91.
A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis.
By the way, doctor. Cancer of the small intestine. Harv Health Lett. 2008 May; 33(7):7.
By the way, doctor. Cancer of the small intestine.
Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton SR, Ismail MK, Jasperson K, Lazenby AJ, Lynch PM, Martin EW, Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010 Jan; 8(1):8-61.
NCCN clinical practice guidelines in oncology. Colorectal cancer screening.
Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 01; 33(31):3598-607.
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M
The journal of allergy and clinical immunology. In practice
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.
Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016 08 10; 34(23):2736-42.
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 09 01; 34(25):3047-53.
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
Physician Scientist Training in Cancer Research
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM
Bertagnolli MM, Compton CC, Niedzwiecki D, Warren RS, Jewell S, Bailey GP, Mayer RJ, Goldberg R, Saltz L, Redston M
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10003.
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer.
Benson AB, Catalan P, Meropol NJ, Giantonio BJ, Sigurdson ER, Martenson JA, Whitehead RP, Sinicrope F, Mayer RJ, O'Dwyer PJ
ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5- fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/ III rectal cancer receiving either pre or postoperative radiation (RT)/ FU. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3526.
ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5- fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/ III rectal cancer receiving either pre or postoperative radiation (RT)/ FU.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas C, Mayer RJ, Haddock MG, Willett C, Willett C, Rich TA
Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4009.
Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal.
Fuchs C, Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Bertagnolli MM
KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2009 May 20; 27(15_suppl):4037.
KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803.
Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG
Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival. J Clin Oncol. 2011 Feb; 29(4_suppl):367.
Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival.
Bertagnolli MM, Niedzwiecki D, Hall M, Jewell SD, Mayer RJ, Goldberg RM, Colacchio TA, Warren RS, Redston M
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. J Clin Oncol. 2009 May 20; 27(15_suppl):4012.
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581.
Farag SS, Ruppert A, Mrozek K, Kolitz JE, Mayer RJ, Carroll AJ, Powell BL, Moore JO, Larson RA, Bloomfield CD
Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic stem cell transplantation (ASCT) for acute myeloid leukemia (AML) patients <60 years with normal cytogenetics: A Cancer and Leukemia Group B (CALGB) Study. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6542.
Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic stem cell transplantation (ASCT) for acute myeloid leukemia (AML) patients <60 years with normal cytogenetics: A Cancer and Leukemia Group B (CALGB) Study.
Lenz HJ, Mayer RJ, Gold PJ, Mirtsching B, Stella PJ, Cohn AL, Pippas AW, Azarnia N, Needle MN, Van Cutsem E
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3510.
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin.
Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ
Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011 May 20; 29(15_suppl):4003.
Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.
Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Carver G, Mayer RJ
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3500.
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803).
Ryan DP, Niedzwiecki D, Hollis D, Miedema BE, Wadler S, Tepper JE, Mayer RJ
A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3560.
A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901.
Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ
A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). J Clin Oncol. 2004 Jul 15; 22(14_suppl):4011.
A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904).
Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. J Clin Oncol. 2011 May 20; 29(15_suppl):4005.
Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin.
Reply to L. Casadaban et al. J Clin Oncol. 2017 04 20; 35(12):1373-1374.
Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017 Apr 01; 35(10):1086-1095.
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD
Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol. 1996 Sep; 14(9):2486-94.
Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
Adjuvant Chemotherapy for Colon and Rectal Cancer. Semin Radiat Oncol. 1993 Jan; 3(1):29-41.
Adjuvant Chemotherapy for Colon and Rectal Cancer.
Miller RC, Sargent DJ, Martenson JA, Macdonald JS, Haller D, Mayer RJ, Gunderson LL, Rich TA, Cha SS, O'Connell MJ
Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):409-13.
Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial.
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O'Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB, Fuchs CS
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004 Feb 15; 22(4):648-57.
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
Steele G, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991 Jul; 9(7):1105-12.
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584.
Larson RA, Stone RM, Mayer RJ, Schiffer CA
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3556s-63s.
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.
O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997 Jan; 15(1):246-50.
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.
Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Leichman CG, Macdonald JS
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006 Aug 01; 24(22):3542-7.
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
Third International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Cologne, 23-26 September 1998. Ann Oncol. 1999 Mar; 10(3):281-7.
Third International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Cologne, 23-26 September 1998.
Chemoprevention of colorectal cancer. N Engl J Med. 2000 Jun 29; 342(26):1960-8.
Evans JS, Ford BM, Balmaña J, Stoffel EM, Mayer RJ, Syngal S
Factors predicting willingness to participate in cancer genetic epidemiologic research. J Clin Oncol. 2005 Jun; 23(16_suppl):6007.
Factors predicting willingness to participate in cancer genetic epidemiologic research.
Jackson NA, Fuchs CS, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Meyerhardt JA
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803. J Clin Oncol. 2008 May 20; 26(15_suppl):4039.
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803.
Pippas AW, Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Windt P, van Cutsem E
Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. J Clin Oncol. 2005 Jun; 23(16_suppl):3595.
Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy.
Fuchs C, Meyerhardt JA, Heseltine DL, Niedzwiecki D, Hollis D, Chan AT, Saltz LB, Schilsky RL, Mayer RJ
Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 Jun; 23(16_suppl):3530.
Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803.
Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Pippas A, Windt P, van Cutsem E
Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):3536.
Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer.
Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schilsky RL, Fuchs CS
The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 Jun; 23(16_suppl):3534.
The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803.
Greenberg DB, Kornblith AB, Herndon JE, Zuckerman E, Schiffer CA, Weiss RB, Mayer RJ, Wolchok SM, Holland JC
Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress. Cancer. 1997 Nov 15; 80(10):1936-44.
Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress.
Silverman SG, Khorasani R, Adams DF, Phillips MD, Sica GT, Mayer RJ
Multidisciplinary gastrointestinal cancer clinic: abdominal radiologist as active participant. Acad Radiol. 1998 Oct; 5(10):694-7.
Multidisciplinary gastrointestinal cancer clinic: abdominal radiologist as active participant.
Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ
Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997 Feb; 112(2):594-642.
Colorectal cancer screening: clinical guidelines and rationale.
Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367.
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera
Efficacy of neo- and adjuvant treatment modalities in gastrointestinal cancer patients. Swiss Surg. 2001; 7(6):239-42.
Efficacy of neo- and adjuvant treatment modalities in gastrointestinal cancer patients.
Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, Stuart KE
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002 Jun 15; 94(12):3186-91.
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.
Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS
Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol. 2005 Mar 20; 23(9):1819-25.
Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
Carcinoma of the anal canal. N Engl J Med. 2000 Mar 16; 342(11):792-800.
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997 Feb; 15(2):466-75.
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.
Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD
Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 May; 15(5):1786-95.
Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.
Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD
Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 1991 Mar; 5(3):230-8.
Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Kornblith AB, Herndon JE, Zuckerman E, Cella DF, Cherin E, Wolchok S, Weiss RB, Diehl LF, Henderson E, Cooper MR, Schiffer C, Canellos GP, Mayer RJ, Silver RT, Schilling A, Peterson BA, Greenberg D, Holland JC
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol. 1998 Mar; 9(3):297-306.
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B.
Steele GD, Herndon JE, Bleday R, Russell A, Benson A, Hussain M, Burgess A, Tepper JE, Mayer RJ
Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol. 1999 Jul-Aug; 6(5):433-41.
Sphincter-sparing treatment for distal rectal adenocarcinoma.
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Sarno E, Frei E
Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B. Leukemia. 1992; 6 Suppl 2:66-7.
Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B.
Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, Haller DG
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med. 2002 Feb 19; 136(4):261-9.
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.
Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med. 2003 Oct 21; 139(8):649-57.
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence.
Gastrointestinal cancer in older patients. Semin Oncol. 2004 Apr; 31(2):206-19.
Gastrointestinal cancer in older patients.
Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB, Cummings B, Gunderson L, Macdonald JS, Mayer RJ
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001 Jan 01; 19(1):157-63.
Impact of number of nodes retrieved on outcome in patients with rectal cancer.
Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63.
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002 Sep-Oct; 8(5):395-9.
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.
Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S
Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 Jul 01; 35(19):2165-2172.
Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome.
Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 01; 26(7):1086-92.
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000 Jul; 12(4):345-52.
Anal carcinoma: histology, staging, epidemiology, treatment.
Targeted therapy for advanced colorectal cancer--more is not always better. N Engl J Med. 2009 Feb 05; 360(6):623-5.
Targeted therapy for advanced colorectal cancer--more is not always better.
Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM
Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol. 1992 Jun; 10(6):948-53.
Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.
Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011 Jun 15; 117(12):2620-8.
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Tepper JE, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol. 2003 Oct 01; 21(19):3623-8.
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114.
Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96.
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG
Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003 Aug 01; 21(15):2912-9.
Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.
Phase II study of methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in advanced colorectal cancer. J Clin Oncol. 1984; 2:770-773.
Phase II study of methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in advanced colorectal cancer
Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec; 50(12):2218-23.
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.
Mrózek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD
Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood. 1997 Dec 01; 90(11):4532-8.
Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.
Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007 Aug 10; 25(23):3456-61.
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007 Aug 15; 298(7):754-64.
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 01; 24(22):3535-41.
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991 Dec; 9(12):2128-33.
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol. 2007 Sep 20; 25(27):4165-7.
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Two steps forward in the treatment of colorectal cancer. N Engl J Med. 2004 Jun 03; 350(23):2406-8.
Two steps forward in the treatment of colorectal cancer.
Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol. 1992 Apr; 10(4):536-40.
Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial.
O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May 01; 19(9):2413-21.
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J Clin Oncol. 2001 Nov 01; 19(21):4093-6.
Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar; 20(3):475-80.
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 01; 15(23):7322-9.
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
Lokich JJ, Skarin AT, Mayer RJ, Henderson IC, Blum RH, Frei E
Adriamycin plus alkylating agents in the treatment of metastatic breast cancer. Cancer. 1977 Dec; 40(6):2801-5.
Adriamycin plus alkylating agents in the treatment of metastatic breast cancer.
Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10; 30(35):4344-51.
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Tripp DA, Nickel JC, Fitzgerald MP, Mayer R, Stechyson N, Hsieh A
Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. Urology. 2009 May; 73(5):987-92.
Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome.
Rau P, Steele G Jr, Mayer R, Wilson RE, Zamcheck N
The rate of postoperative CEA rise in selecting treatment for recurrent colorectal cancer. Gastroenterology. 1979; 76:1223.
The rate of postoperative CEA rise in selecting treatment for recurrent colorectal cancer
Jessup JM, Bothe A Jr, Stone MD, Gray C, Bleday R, Busse PM, Huberman M, Mayer RJ, Steele G Jr.
Preservation of sphincter function in rectal carcinoma by a multimodality treatment approach. Surg Clin N Am. 1992; 1:137-145.
Preservation of sphincter function in rectal carcinoma by a multimodality treatment approach
Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS
A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004; 22(3):353-9.
A phase II study of docetaxel in patients with metastatic carcinoid tumors.
Central nervous system involvement by ovarian carcinoma: a complication of prolonged survivial with metastatic disease. Cancer. 1978 Feb; 41(2):776-83.
Central nervous system involvement by ovarian carcinoma: a complication of prolonged survivial with metastatic disease.
Frei E, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980 Mar; 68(3):370-6.
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.
Systemic therapy for colorectal cancer. N Engl J Med. 2005 Feb 03; 352(5):476-87.
Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES
Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 1973 Oct; 32(4):771-88.
Cardiac ultrastructural changes induced by daunorubicin therapy.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23; 299(16):1914-21.
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 Apr 10; 27(11):1814-21.
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009 Mar 15; 15(6):2116-22.
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 01; 27(7):1116-21.
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.
King JC, Lawrence TS, Murphy SB, Davidson NE, Mayer RJ
The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future. J Clin Oncol. 2010 Mar 20; 28(9):1616-21.
The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future.
By the way, doctor. I read that President Obama had a virtual colonoscopy. Is this the colon cancer screening test that everybody should be getting instead of a regular colonoscopy? I thought it was kind of experimental. Harv Health Lett. 2010 Jun; 35(8):8.
By the way, doctor. I read that President Obama had a virtual colonoscopy. Is this the colon cancer screening test that everybody should be getting instead of a regular colonoscopy? I thought it was kind of experimental.
Acute lymphoblastic leukemia in adults. Ann Intern Med. 1984 Oct; 101(4):552-4.
Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloomfield CD
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994 Mar 15; 83(6):1603-11.
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.
Haller DG, Lefkopoulou M, Macdonald JS, Mayer RS
Advances in experimental medicine and biology
Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089). Adv Exp Med Biol. 1993; 339:51-4; discussion 55-6.
Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089).
Levin B, Barthel JS, Burt RW, David DS, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton S, Kohlmann W, Ludwig KA, Lynch PM, Marino C, Martin EW, Mayer RJ, Pasche B, Pirruccello SJ, Rajput A, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Winawer SJ
Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):384-420.
Colorectal Cancer Screening Clinical Practice Guidelines.
Leape LL, Shore MF, Dienstag JL, Mayer RJ, Edgman-Levitan S, Meyer GS, Healy GB
Academic medicine : journal of the Association of American Medical Colleges
Perspective: a culture of respect, part 2: creating a culture of respect. Acad Med. 2012 Jul; 87(7):853-8.
Perspective: a culture of respect, part 2: creating a culture of respect.
Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, McIntyre OR, Bloomfield CD
Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood. 1986 Dec; 68(6):1232-41.
Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia.
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22.
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Green MD, Stablein DM, Douglass HO Jr., Mayer RJ
A prospective trial of rcombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma. Cancer. 1990; 66:135-139.
A prospective trial of rcombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma
Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JM, Bem J, Mayer RJ, Bertagnolli MM
Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol. 2006 Feb 20; 24(6):878-83.
Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001.
Mayer RJ, Weinstein HJ, Rosenthal DS, Coral FS, Nathan DG, Frei E
VAPA10: a treatment program for acute myelocytic leukemia. Haematol Blood Transfus. 1981; 26:45-52.
VAPA10: a treatment program for acute myelocytic leukemia.
Overview: the changing nature of esophageal cancer. Chest. 1993 Apr; 103(4 Suppl):404S-405S.
Overview: the changing nature of esophageal cancer.
Ryan DP, Lynch TJ, Grossbard ML, Seiden MV, Fuchs CS, Grenon N, Baccala P, Berg D, Finkelstein D, Mayer RJ, Clark JW
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer. 2000 Jan 01; 88(1):180-5.
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB, Macdonald JS, Fuchs CS
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003 Aug 01; 98(3):484-95.
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004 Apr 01; 22(7):1201-8.
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004 Oct; 27(5):485-8.
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.
Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 01; 23(34):8671-8.
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990 Nov; 8(11):1913-21.
The unique aspects of acute promyelocytic leukemia.
Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008 Jun 04; 299(21):2515-23.
Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW
Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986 Nov; 46(11):5953-8.
Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.
Prognostic factors for colon cancer. J Clin Oncol. 1988 Jun; 6(6):1066-7.
Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677.
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
Gastric carcinoma. N Engl J Med. 1995 Jul 06; 333(1):32-41.
Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW
Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol. 1993 Apr; 16(2):159-63.
Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes.
Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002 Jan 01; 94(1):97-103.
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Farag SS, Archer KJ, Mrózek K, Vardiman JW, Carroll AJ, Pettenati MJ, Moore JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov; 21(5):1041-51.
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205.
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ
Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007 May-Jun; 57(3):168-85.
Adjuvant treatment of colorectal cancer.
Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, Kolitz J, Baer MR, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42.
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.
Bloomfield CD, Ruppert AS, Mrózek K, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol. 2004; 83 Suppl 1:S84-5.
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
Steele G, Sonis S, Stelos P, Rittgers R, Zamcheck N, Finn D, Maltz J, Mayer R, Lokich J, Wilson RE
Circulating immune complexes in patients following clinically curative resection of colorectal cancer. Surgery. 1978 Jun; 83(6):648-54.
Circulating immune complexes in patients following clinically curative resection of colorectal cancer.
Systemic treatment of colorectal cancer. Gastroenterology. 2008 May; 134(5):1296-310.
Systemic treatment of colorectal cancer.
Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008 Oct 01; 26(28):4603-9.
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
Rittgers RA, Steele G, Zamcheck N, Loewenstein MS, Sugarbaker PH, Mayer RJ, Lokich JJ, Maltz J, Wilso RE
Transient carcinoembryonic antigen (CEA) elevations following resection of colorectal cancer: a limitation in the use of serial CEA levels as an indicator for second-look surgery. J Natl Cancer Inst. 1978 Aug; 61(2):315-8.
Transient carcinoembryonic antigen (CEA) elevations following resection of colorectal cancer: a limitation in the use of serial CEA levels as an indicator for second-look surgery.
Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51.
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
Phase II trials of the simple agents Baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Cancer Treat ep. 1987; 71:865-867.
Phase II trials of the simple agents Baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer
Bertagnolli M, Miedema B, Redston M, Dowell J, Niedzwiecki D, Fleshman J, Bem J, Mayer R, Zinner M, Compton C
Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg. 2004 Oct; 240(4):624-8; discussion 628-30.
Sentinel node staging of resectable colon cancer: results of a multicenter study.
Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17.
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Goldberg RM, Niedzwiecki D, Bertagnolli M, Blackstock AW, Tepper JE, Mayer RJ
Cancer and leukemia group B gastrointestinal cancer committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3589s-95s.
Cancer and leukemia group B gastrointestinal cancer committee.
Diagnostic dilemmas in oncology. Case 3. Metastatic ovarian cancer simulating colon cancer. J Clin Oncol. 2000 Sep; 18(17):3189-92.
Diagnostic dilemmas in oncology. Case 3. Metastatic ovarian cancer simulating colon cancer.
Journal of cancer research and clinical oncology
Acute leukemias in adults: an overview of recent strategies. J Cancer Res Clin Oncol. 1990; 116(1):94-6.
Acute leukemias in adults: an overview of recent strategies.
Bruckner HW, Petrelli NJ, Stablein D, Novak J, Mayer R
NCI monographs : a publication of the National Cancer Institute
Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies. NCI Monogr. 1987; (5):179-84.
Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies.
Blum RH, Wittenberg BK, Canellos GP, Mayer RJ, Skarin AT, Henderson IC, Parker LM, Frei E
A therapeutic trial of maytansine. Cancer Clin Trials. 1978; 1(2):113-7.
Karp GI, von Oeyen P, Valone F, Khetarpal VK, Israel M, Mayer RJ, Frigoletto FD, Garnick MB
Doxorubicin in pregnancy: possible transplacental passage. Cancer Treat Rep. 1983 Sep; 67(9):773-7.
Doxorubicin in pregnancy: possible transplacental passage.
Todd RF, Garnick MB, Canellos GP, Richie JP, Gittes RF, Mayer RJ, Skarin AT
Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma. Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):17-20.
Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma.
McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002 Aug 07; 94(15):1160-7.
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer.
Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS
Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003 Feb 01; 21(3):433-40.
Impact of diabetes mellitus on outcomes in patients with colon cancer.
Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004 Dec 10; 112(5):754-9.
Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.
Mayer RJ, O'Connell MJ, Tepper JE, Wolmark N
Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst. 1989 Sep 20; 81(18):1359-64.
Status of adjuvant therapy for colorectal cancer.
Steele G, Busse P, Huberman MS, LeClair JM, Falchuk ZM, Mayer RJ, Bothe A, Ravikumar TS, Stone M, Jessup JM
A pilot study of sphincter-sparing management of adenocarcinoma of the rectum. Arch Surg. 1991 Jun; 126(6):696-701; discussion 701-2.
A pilot study of sphincter-sparing management of adenocarcinoma of the rectum.
Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians. Acad Med. 2012 Jul; 87(7):845-52.
Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians.
Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a "best choice"? J Clin Oncol. 1988 Oct; 6(10):1532-6.
Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a "best choice"?
Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25.
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin TP, Hall MJ, Llor X, Chung DC, Ahnen DJ, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Halverson AL, Hamilton SR, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Markowitz AJ, Mayer RJ, Ness RM, Samadder NJ, Shike M, Sugandha S, Weiss JM, Dwyer MA, Ogba N
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. J Natl Compr Canc Netw. 2017 12; 15(12):1465-1475.
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017.
Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol. 2011 Aug 10; 29(23):3153-62.
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
Greenberg JA, Shibata D, Herndon JE, Steele GD, Mayer R, Bleday R
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum. 2008 Aug; 51(8):1185-91; discussion 1191-4.
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.
Pregnancy and leukemia. Semin Oncol. 1989 Oct; 16(5):388-96.
Barkin JS, Cohen ME, Flaxman M, Lindblad AS, Mayer RJ, Kalser MH, Steinberg SM
The American journal of gastroenterology
Value of a routine follow-up endoscopy program for the detection of recurrent colorectal carcinoma. Am J Gastroenterol. 1988 Dec; 83(12):1355-60.
Value of a routine follow-up endoscopy program for the detection of recurrent colorectal carcinoma.
Li FP, Little JB, Bech-Hansen NT, Paterson MC, Arlett C, Garnick MB, Mayer RJ
Acute leukemia after radiotherapy in a patient with Turcot's syndrome. Impaired colony formation in skin fibroblast cultures after irradiation. Am J Med. 1983 Feb; 74(2):343-8.
Acute leukemia after radiotherapy in a patient with Turcot's syndrome. Impaired colony formation in skin fibroblast cultures after irradiation.
Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG, Frei E
Treatment of acute myelogenous leukemia in children and adults. N Engl J Med. 1980 Aug 28; 303(9):473-8.
Treatment of acute myelogenous leukemia in children and adults.
Sandler DP, Shore DL, Anderson JR, Davey FR, Arthur D, Mayer RJ, Silver RT, Weiss RB, Moore JO, Schiffer CA
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst. 1993 Dec 15; 85(24):1994-2003.
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow.
Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Fuchs CS
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2010 Oct 01; 28(28):4354-63.
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.
Schein PS, Stablein DM, Bruckner HW, Douglass HO Jr, Mayer R, Ramming K, et. al.
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer. 1982; 49:1771-1777.
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma
Talcott JA, Finberg R, Mayer RJ, Goldman L
The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988 Dec; 148(12):2561-8.
The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.
Primary gastrointestinal lymphoma. Semin Oncol. 1988 Apr; 15(2):154-69.
Mayer RJ, Schiffer CA, Peterson BA, Budman DR, Silver RT, Rai KR, Cornwell GG, Ellison RR, Maguire M, Berg DT
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. Semin Oncol. 1987 Jun; 14(2 Suppl 1):25-31.
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B.
Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, Silver RT, Peterson BA, Weiss RB, Omura GA, Mayer RJ, Van Echo DA, Bloomfield CD, Schilsky RL
Clinical pharmacology of cytarabine in patietns with acute myeloid leukemia: a Cancer and Leukemia Group B study. Cancer Chemother and Pharmacol. 1995; 36:425-430.
Clinical pharmacology of cytarabine in patietns with acute myeloid leukemia: a Cancer and Leukemia Group B study
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol. 1992; 10:549-557.
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum
Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP
Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore). 1979 Sep; 58(5):377-84.
Microangiopathic hemolytic anemia and cancer: a review.
Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011 Aug 10; 29(23):3146-52.
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol. 2012 Sep 20; 30(27):3325-7.
Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought.
Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999 Dec; 17(12):3767-75.
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.
Esophageal cancer. N Engl J Med. 2003 Dec 04; 349(23):2241-52.
Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94.
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
Arnold CN, Goel A, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther. 2004 Oct; 3(10):960-4.
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q.
Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA
International journal of gastrointestinal cancer
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34(2-3):107-16.
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Winning the war on cancer. N Engl J Med. 1997 Sep 25; 337(13):935; author reply 937-8.
Carcinoid tumors. N Engl J Med. 1999 Mar 18; 340(11):858-68.
Merkel cell carcinoma. J Clin Oncol. 2002 Jan 15; 20(2):588-98.
Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol. 2002 Apr 01; 20(7):1744-50.
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114.
Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, Silver RT, Peterson BA, Weiss RB, Omura GA, Mayer RJ, Van Echo DA, Bloodfield CD, Schilsky RL
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study. Cancer Chemother and Pharmacol. 1995; 36:425-430.
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study
Steele G, Zamcheck N, Wilson R, Mayer R, Lokich J, Rau P, Maltz J
Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surg. 1980 Apr; 139(4):544-8.
Results of CEA-initiated second-look surgery for recurrent colorectal cancer.
Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2018 04 10; 36(11):1112-1120.
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).